Daphne Day

ADJUNCT LECTURER, Medicine Monash Health
Medical Oncologist , Medicine Monash Health
Medicine Monash Health

https://orcid.org/0000-0001-8262-2441

Research activity per year

If you made any changes in Pure these will be visible here soon.

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

1 Finished
10 Active

A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and levnatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Day, D.
28/08/20 → 27/08/25
Project: Research
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Day, D.
21/07/20 → 20/07/25
Project: Research
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy
Day, D.
24/02/20 → 23/02/25
Project: Research
A Phase I study of MAX-10181 given orally to patients with advanced solid tumors
Day, D. & Frentzas, S.
10/02/20 → 9/02/25
Project: Research
A Phase la/lb, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Day, D. & Markman, B.
6/06/19 → 5/06/24
Project: Research

10 Article
2 Chapter (Book)
2 Meeting Abstract
2 Editorial
More
- 2 Review Article
- 1 Comment / Debate

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature
David, S., Ho, G., Day, D., Harris, M., Tan, J., Goel, S., Hanna, G. G., Srivastava, R., Kruss, G., McDowell, L. & White, M., Jan 2021, In : Translational Oncology. 14, 1, 7 p., 100939.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
Impact of the CoviD-19 epidemic on a pan-Asian academic oncology clinical trial
Segelov, E., Prenen, H., Day, D., Raina Macintyre, C., Foo, E. M. J., Ali, R., Wang, Q., Wei, X., de Lima Lopes, G., Ding, K., Chen, G., Chia, J. W. K., Toh, H. C. & on behalf of the ASCOLT Investigators, 1 Jan 2020, In : JCO Global Oncology. 6, p. 585-588 4 p.
Research output: Contribution to journal › Comment / Debate › Other › peer-review

Open Access

6 Citations (Scopus)
Recruitment, outcomes and toxicity trends in phase I oncology trials: six-year experience in a large institution
Menon, S., Davies, A., Frentzas, S., Hawkins, C-A., Segelov, E., Day, D. & Markman, B., Nov 2020, In : Asia-Pacific Journal of Clinical Oncology. p. 154-154 1 p.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review
Current Utility and Future Applications of ctDNA in Colorectal Cancer
Day, D., Frentzas, S., Naidu, C. A., Segelov, E. & Green, M., 6 Feb 2019, Advances in the Molecular Understanding of Colorectal Cancer. Segelov, E. (ed.). In-Tech, 24 p.
Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research

Open Access
File
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., Chappell, M., Chow, K., Sherwin, B., Stayner, L. A., Soultani, L., Zambrana, A., Siu, L. L., Bedard, P. L. & Spreafico, A., Jan 2019, In : European Journal of Cancer. 107, p. 1-7 7 p.
Research output: Contribution to journal › Article › Research › peer-review

12 Citations (Scopus)